Axogen Inc. Q2 2026 Financial Results

Axogen, Inc. reported its second quarter 2026 financial results, with revenue reaching $69.7 million, a 23.1% increase year-over-year. The company raised its full-year revenue guidance to at least 24% growth, projecting revenues of at least $279 million. Gross margin was 72.7%, compared to 74.2% in Q2 2025. The net loss for the quarter was $1.5 million, or $0.03 per share, a shift from a net income of $0.6 million in Q2 2025. Adjusted net income was $7.3 million, or $0.12 per share. Adjusted EBITDA was $8.4 million. The company highlighted broad-based revenue growth across its target markets, the publication of the REPOSE study, the initiation of the Nerve-RESTORE study, and a strategic investment in Trace Biosciences. Axogen ended the quarter with $113.4 million in cash, cash equivalents, restricted cash, and investments.